CoChat

Ethics of Cancer Gene Transfer Clinical Research

Kimmelman, Jonathan · 2015 · Methods in Molecular Biology
Cited by 2

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-1-4939-2727-2_15

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 83

  1. Pearson S, Jia H, Kandachi K (2004) China approves first gene therapy. Nat Biotechnol 22(1):3–4 · DOI · Paper page
  2. Anderson C (1993) Gene therapy. A speeding ticket for NIH's controversial cancer star. Science 259(5100):1391–1392 · doi:10.1126/science.8338519
  3. Garber K (1999) RAC nixes plan to treat retinoblastoma. Science 284(5423):2066 · doi:10.1126/science.284.5423.2066a
  4. Office GP (1949) Nuremberg code. In: Government Printing Office (ed) Trials of war criminals before the Nuremberg military tribunals under control council law no. 10, vol 2. GPO, Washington, DC, pp 181–182
  5. Henderson VC et al (2013) Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med 10(7):e1001489 · DOI · Paper page
  6. Lefer DJ, Bolli R (2011) Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther 16(3–4):332–339 · DOI · Paper page
  7. Shineman DW et al (2011) Accelerating drug discovery for Alzheimer’s disease: best practices for preclinical animal studies. Alzheimers Res Ther 3(5):28 · DOI · Paper page
  8. Kilkenny C et al (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412 · DOI · Paper page
  9. Danos O et al (2010) The ARRIVE guidelines, a welcome improvement to standards for reporting animal research. J Gene Med 12(7):559–560 · DOI
  10. Crystal RG (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270(5235):404–410 · DOI · Paper page
  11. Kimmelman J (2005) Recent developments in gene transfer: risk and ethics. BMJ 330(7482):79–82 · DOI
  12. Westberg S et al (2013) Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36(6):350–358 · DOI
  13. Finocchiaro LM, Glikin GC (2012) Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Ther 19(12):852–861 · doi:10.1038/cgt.2012.72
  14. Modiano JF et al (2012) Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther 20(12):2234–2243 · DOI
  15. Kimmelman J, Nalbantoglu J (2007) Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res 67(10):4541–4544 · DOI
  16. Weijer C, Miller PB (2004) When are research risks reasonable in relation to anticipated benefits? Nat Med 10(6):570–573 · DOI · Paper page
  17. Freedman B (1987) Equipoise and the ethics of clinical research. N Engl J Med 317(3):141–145 · DOI · Paper page
  18. Kimmelman J (2004) Valuing risk: the ethical review of clinical trial safety. Kennedy Inst Ethics J 14(4):369–393 · doi:10.1353/ken.2004.0041
  19. London AJ (2006) Reasonable risks in clinical research: a critique and a proposal for the integrative approach. Stat Med 25(17):2869–2885 · DOI
  20. London AJ, Kimmelman J, Emborg ME (2010) Research ethics. Beyond access vs. protection in trials of innovative therapies. Science 328(5980):829–830 · DOI · Paper page
  21. Morral N et al (2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13(1):143–154 · DOI · Paper page
  22. Kimmelman J, London AJ (2011) Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 8(3):e1001010 · DOI · Paper page
  23. Anderson JA, Kimmelman J (2010) Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst Ethics J 20(1):75–98 · DOI
  24. Kimmelman J (2012) A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. Trials 13(1):173 · DOI
  25. Hay M et al (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32(1):40–51 · DOI · Paper page
  26. Kimmelman J (2010) Gene transfer and the ethics of first-in-human research: Lost in Translation. Cambridge University Press, Cambridge, UK
  27. Orkin SH, Motulsky AG (1995) Report and Recommendations of the Panel to Asses the NIH Investment in Research on Gene Therapy. National Institutes of Health - Office of Biotechnology Activities, Editor
  28. Albelda SM, Sterman DH (2004) TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials. J Clin Oncol 22(4):577–579 · doi:10.1200/jco.2004.12.964
  29. Spencer Phillips H, Jonathan K (2014) The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 24(2):121–139 · DOI
  30. Overman MJ et al (2013) Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 31(1):17–22 · DOI · Paper page
  31. Kimmelman J, Lemmens T, Kim SY (2012) Analysis of consent validity for invasive, nondiagnostic research procedures. IRB 34(5):1–7
  32. Helft P, Daugherty C (2006) Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 24:4793–4795 · DOI
  33. Peppercorn J et al (2010) Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 28(15):2635–2640 · DOI
  34. Olson EM et al (2011) The ethical use of mandatory research biopsies. Nat Rev Clin Oncol 8(10):620–625 · DOI
  35. Pentz RD et al (2012) Research biopsies in phase I studies: views and perspectives of participants and investigators. IRB 34(2):1–8
  36. Agulnik M et al (2006) Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24:4801–4807 · DOI
  37. Abadie R et al (2014) Consent for nondiagnostic research biopsies: a pilot study of participant recall and therapeutic orientation. IRB 36(3):9–15
  38. Freeman GA, Kimmelman J (2012) Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early phase oncology trials. Clin Cancer Res 18(23):6478–6484 · DOI
  39. Freeman GA et al (2013) Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials. Br J Cancer 109(4):897–908 · DOI
  40. Liu SC et al (2002) Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 9(4):291–296 · DOI · Paper page
  41. Sasaki T et al (2006) Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci 97(7):649–657 · DOI · Paper page
  42. Kimmelman J (2005) Medical research, risk, and bystanders. IRB 27(4):1–6 · DOI
  43. Lichtenstein DL, Wold WS (2004) Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11(12):819–829 · DOI
  44. Griscelli F et al (2003) Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 10(5):386–395 · DOI
  45. Schenk-Braat EA et al (2007) An inventory of shedding data from clinical gene therapy trials. J Gene Med 9(10):910–921 · DOI · Paper page
  46. Favaro P et al (2009) Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mol Ther 17(6):1022–1030 · DOI · Paper page
  47. Couto L, Parker A, Gordon JW (2004) Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction. Hum Gene Ther 15(3):287–291 · DOI
  48. Sherwin S (2005) Belmont revisited through a feminist lens. In: Childress JF, Meslin EM, Shapiro HT (eds) Belmont revisited: ethical principles for research with human subjects. Georgetown University Press, Washington DC, pp 148–164
  49. Einhorn B, Carey J, Hall K (2006) A cancer treatment you can't get here: China, with lower regulatory hurdles, is racing to a lead in gene therapy, in Business Week
  50. Jia H, Kling J (2006) China offers alternative gateway for experimental drugs. Nat Biotechnol 24(2):117–118 · DOI
  51. World Medical Association Declaration of Helsinki (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194 · DOI · Paper page
  52. Council for International Organizations of Medical Sciences (CIOMS) (2002) International ethical guidelines for biomedical research involving human subjects. World Health Organization, Geneva
  53. National Bioethics Advisory Commission (2001) Ethical and policy issues in international research: clinical trials in developing countries In: Volume I: report and recommendations of the National Bioethics Advisory Commission. National Bioethics Advisory Commission, Bethesda, MD
  54. Nuffield Council on Bioethics (2002) The ethics of research related to healthcare in developing countries. Nuffield Council on Bioethics, London
  55. London AJ (2005) Justice and the human development approach to international research. Hastings Cent Rep 35(1):24–37
  56. Jia H (2006) Controversial Chinese gene-therapy drug entering unfamiliar territory. Nat Rev Drug Discov 5(4):269–270 · doi:10.1038/nrd2017
  57. Lysaught MT (1998) Commentary: reconstruing genetic research as research. J Law Med Ethics 26(1):48–54 · DOI
  58. Jenks S (1993) RAC approves policy for single-patient use of gene therapy. J Natl Cancer Inst 85(4):266–267 · doi:10.1093/jnci/85.4.266
  59. Faden RR, Beauchamp TL, King NMP (1986) A history and theory of informed consent, vol xv. Oxford University Press, New York, p 392
  60. Appelbaum PS et al (1987) False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 17(2):20–24 · DOI · Paper page
  61. Lidz CW et al (2004) Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med 58(9):1689–1697 · DOI · Paper page
  62. Cheng JD et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18(2):421–428 · DOI · Paper page
  63. Daugherty C et al (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13(5):1062–1072 · DOI · Paper page
  64. Sulmasy DP et al (2010) The culture of faith and hope: patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116(15):3702–3711 · DOI · Paper page
  65. Weinfurt KP (2007) Value of high-cost cancer care: a behavioral science perspective. J Clin Oncol 25(2):223–227 · DOI
  66. King NM (2000) Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 28(4):332–343 · DOI · Paper page
  67. Mathieu S et al (2009) Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302(9):977–984 · DOI · Paper page
  68. Niraula S et al (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30(24):3012–3019 · DOI · Paper page
  69. Sivendran S et al (2014) Adverse event reporting in cancer clinical trial publications. J Clin Oncol 32(2):83–89 · DOI
  70. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43(17):2559–2579 · DOI · Paper page
  71. Laine C et al (2007) Clinical trial registration: looking back and moving ahead. Ugeskr Laeger 169(26):2505–2506
  72. World Medical Association (2008) Declaration of Helsinki – ethical principles for medical research involving human subjects · DOI · Paper page
  73. Camacho LH et al (2005) Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 104(7):1497–1504 · DOI · Paper page
  74. Hoeg RT et al (2009) Publication outcomes of phase II oncology clinical trials. Am J Clin Oncol 32(3):253–257 · DOI
  75. Chang SM et al (2005) GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 7(4):425–434 · DOI
  76. McShane LM et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184 · DOI · Paper page
  77. Fournier L et al (2014) Imaging criteria for assessing tumour response: RECIST, mRECIST. Cheson, Diagn Interv Imaging
  78. Cabo II (2002) Immunology and gene therapy. Mol Ther 5(5):486–491 · DOI
  79. Advisory Committee on Human Radiation Experiments (1995) Final report. Advisory Committee on Human Radiation Experiments, Washington, DC
  80. Kolata G (1998) Hope in the lab: a special report. A cautious awe greets drugs that eradicate tumors in mice. The New York Times, New York, p 1
  81. Bogler O, Mikkelsen T (2003) Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 9(3):205–213 · DOI
  82. Ryan DP et al (1999) Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist 4(6):501–508 · DOI
  83. Wilson JM (2009) Medicine. A history lesson for stem cells. Science 324(5928):727–728 · DOI · Paper page

Cited by

See all 2

Metadata

Authors
Kimmelman, J.
Venue
Methods in Molecular Biology
Published
2015
Pages
263-285
ISSN
  • 1064-3745
  • 1940-6029
Cited by
2
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ethics of Cancer Gene Transfer Clinical Research. https://app.cochat.ai/papers/10.1007/978-1-4939-2727-2_15
The paper
Kimmelman, J. (2015). Ethics of Cancer Gene Transfer Clinical Research. Methods in Molecular Biology. https://doi.org/10.1007/978-1-4939-2727-2_15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.